Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 4,760 shares at $22.64 ($108K) on 2024-06-11, disclosed to the SEC on 2024-06-13.
Open-market sale of $108k AKRO by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.64 | 2,380 | $54K | 50.0% |
| 2 | $22.64 | 2,380 | $54K | 50.0% |
| Total | $22.64 avg | 4,760 | $108K | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |